Serge Langford
Directeur/Membre du Conseil chez Aegera Therapeutics, Inc.
Profil
Serge Langford is currently a Director at PainCeptor Pharma Corp., Aegera Therapeutics, Inc., and DalCor Pharmaceuticals Canada, Inc. He was formerly a Director at Aurelium BioPharma, Inc., Topigen Pharmaceuticals, Inc., and Thryv Therapeutics, Inc. He was also a Managing Partner at Multiple Capital, Inc. Langford received his undergraduate and graduate degrees from Hautes Etudes Commerciales.
Postes actifs de Serge Langford
| Sociétés | Poste | Début |
|---|---|---|
Aegera Therapeutics, Inc.
 Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | Directeur/Membre du Conseil | - |
PainCeptor Pharma Corp.
 PainCeptor Pharma Corp. Pharmaceuticals: MajorHealth Technology PainCeptor Pharma Corp. operates as a biopharmaceutical company which engages in the development of pharmaceuticals for chronic and acute pain. It offers next generation therapeutic drugs for the treatment of chronic and acute pain. The firms products includes NGF/p75-TrkA, ASIC1a and ASIC3. The company was founded by Louis Lamontagne in 2003 and is headquartered in St-Laurent, Canada. | Directeur/Membre du Conseil | - |
DalCor Pharmaceuticals Canada, Inc.
 DalCor Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada. | Directeur/Membre du Conseil | - |
Anciens postes connus de Serge Langford
| Sociétés | Poste | Fin |
|---|---|---|
Thryv Therapeutics, Inc.
 Thryv Therapeutics, Inc. Medical/Nursing ServicesHealth Services LQT Therapeutics, Inc. engages in the development of therapies for the treatment of all forms of Long QT Syndrome. The company was founded by Anthony Rosenzweig, Saumya Das and David Milan and is headquartered in Laval, Canada. | Directeur/Membre du Conseil | - |
Multiple Capital, Inc.
 Multiple Capital, Inc. Investment ManagersFinance Founded in 2005, formerly Société Innovatech du Grand Montréal, Multiple Capital is a Montréal-based venture capital subsidiary of Collier Capital Ltd. | Private Equity Investor | - |
Topigen Pharmaceuticals, Inc.
 Topigen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Topigen Pharmaceuticals, Inc. develops drugs for respiratory diseases. The firm focuses on discovery and development of multiple pathway therapies for respiratory diseases with primary emphasis on asthma, chronic obstructive pulmonary disease, and allergic rhinitis. The company was founded by Paolo Renzi in 2000 and is headquartered in Montréal, Canada. | Directeur/Membre du Conseil | - |
Aurelium BioPharma, Inc.
 Aurelium BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Aurelium BioPharma Inc., develops therapeutics and diagnostics for the treatment of drug-resistant cancers. The company has developed several diagnostic tests for the detection of breast, ovarian as well as drug-resistant cancers. The firm has a strong drugable pipeline of novel targets and complimentary diagnostic products that are utilized in its strategic collaborations and out-licensing efforts. The company was founded in May 1998 and is headquartered in Laval, Canada. | Directeur/Membre du Conseil | - |
Formation de Serge Langford
| Hautes Etudes Commerciales | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Aurelium BioPharma, Inc.
Aurelium BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Aurelium BioPharma Inc., develops therapeutics and diagnostics for the treatment of drug-resistant cancers. The company has developed several diagnostic tests for the detection of breast, ovarian as well as drug-resistant cancers. The firm has a strong drugable pipeline of novel targets and complimentary diagnostic products that are utilized in its strategic collaborations and out-licensing efforts. The company was founded in May 1998 and is headquartered in Laval, Canada. | Health Technology |
Multiple Capital, Inc.
Multiple Capital, Inc. Investment ManagersFinance Founded in 2005, formerly Société Innovatech du Grand Montréal, Multiple Capital is a Montréal-based venture capital subsidiary of Collier Capital Ltd. | Finance |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | Health Technology |
Topigen Pharmaceuticals, Inc.
Topigen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Topigen Pharmaceuticals, Inc. develops drugs for respiratory diseases. The firm focuses on discovery and development of multiple pathway therapies for respiratory diseases with primary emphasis on asthma, chronic obstructive pulmonary disease, and allergic rhinitis. The company was founded by Paolo Renzi in 2000 and is headquartered in Montréal, Canada. | Health Technology |
PainCeptor Pharma Corp.
PainCeptor Pharma Corp. Pharmaceuticals: MajorHealth Technology PainCeptor Pharma Corp. operates as a biopharmaceutical company which engages in the development of pharmaceuticals for chronic and acute pain. It offers next generation therapeutic drugs for the treatment of chronic and acute pain. The firms products includes NGF/p75-TrkA, ASIC1a and ASIC3. The company was founded by Louis Lamontagne in 2003 and is headquartered in St-Laurent, Canada. | Health Technology |
DalCor Pharmaceuticals Canada, Inc.
DalCor Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada. | Health Technology |
Thryv Therapeutics, Inc.
Thryv Therapeutics, Inc. Medical/Nursing ServicesHealth Services LQT Therapeutics, Inc. engages in the development of therapies for the treatment of all forms of Long QT Syndrome. The company was founded by Anthony Rosenzweig, Saumya Das and David Milan and is headquartered in Laval, Canada. | Health Services |